Lidoject

Lidocaine, the active ingredient in Lidoject, is a local anesthetic presented as a sterile solution for intradermal use. It provides temporary loss of sensation to the skin and underlying tissues, facilitating minor surgical or diagnostic procedures in patients of all ages.

GNH USA supplies Lidoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for importers. Its global logistics network ensures timely delivery across multiple continents.

Lidoject, a lidocaine‑based local anesthetic, is employed to achieve dermal anesthesia for a range of minor procedures.

Minor surgical procedures: provides rapid, reversible loss of sensation at the injection site, facilitating incision, excision or suturing of superficial tissues. Diagnostic skin testing: numbs targeted skin areas to reduce discomfort during biopsies, lesion removal or intradermal testing. Dental interventions: delivers localized anesthesia of oral mucosa for simple extractions, scaling or restorative work.

Lidoject may be associated with a range of adverse reactions, varying from mild local irritation to rare systemic toxicity.

Common Side Effects: - Pain or burning at the injection site - Redness or mild swelling - Transient tingling or numbness

Serious or Rare Side Effects: - Cardiovascular toxicity (arrhythmia, bradycardia, cardiac arrest) - Central nervous system toxicity (seizures, loss of consciousness) - Severe allergic reactions (anaphylaxis, angio‑edema)

When using Lidoject, clinicians should observe several precautions to minimise risk and ensure safe administration.

Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. Cardiovascular status: avoid use in patients with severe heart block, conduction disorders, or uncontrolled arrhythmias. Maximum dose: adhere to recommended total lidocaine dose limits for the patient’s weight and age. Concurrent medications: exercise caution when other sodium‑channel blockers or class I antiarrhythmics are administered. Pregnancy and lactation: consider use only when potential benefit justifies potential risk to the fetus or infant. Store at ambient temperature: keep in original container, protect from light and moisture, and store below 25 °C.

Lidoject can interact with other medicines, altering its safety profile or efficacy.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiotoxicity. - Other local anesthetics: additive systemic toxicity when combined. - Beta‑blockers: may potentiate cardiac depressant effects of lidocaine.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise plasma lidocaine concentrations. - Diuretics (e.g., furosemide): can affect lidocaine clearance and plasma levels. - General anesthetics (e.g., propofol, volatile agents): require monitoring of hemodynamic status.